Relay Therapeutics (NASDAQ:RLAY) Upgraded by Canaccord Genuity Group to “Strong-Buy” Rating

Posted by Brian Himes on Jul 17th, 2026

Canaccord Genuity Group upgraded shares of Relay Therapeutics (NASDAQ:RLAY – Free Report) to a strong-buy rating in a report published on Thursday,Zacks.com reports.

RLAY has been the topic of a number of other research reports. Guggenheim upped their price target on Relay Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, May 26th. Raymond James Financial reissued a “strong-buy” rating on shares of Relay Therapeutics in a report on Tuesday, May 19th. Wall Street Zen upgraded Relay Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. JonesTrading raised shares of Relay Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 19th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a research report on Monday, July 6th. Three analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $24.17.

Get Our Latest Stock Analysis on Relay Therapeutics

Relay Therapeutics Trading Down 0.7%

Relay Therapeutics stock opened at $19.37 on Thursday. Relay Therapeutics has a 12 month low of $3.03 and a 12 month high of $20.79. The business’s 50 day simple moving average is $15.81 and its 200 day simple moving average is $12.27. The company has a market cap of $3.71 billion, a price-to-earnings ratio of -12.34 and a beta of 1.67.

Relay Therapeutics (NASDAQ:RLAY – Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The business had revenue of $3.00 million during the quarter, compared to analyst estimates of $5.58 million. As a group, equities research analysts forecast that Relay Therapeutics will post -1.57 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Relay Therapeutics news, insider Donald A. Bergstrom sold 8,660 shares of the stock in a transaction on Monday, July 6th. The stock was sold at an average price of $18.71, for a total transaction of $162,028.60. Following the sale, the insider owned 409,897 shares in the company, valued at $7,669,172.87. This represents a 2.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Sanjiv Patel sold 48,199 shares of the firm’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $19.58, for a total value of $943,736.42. Following the completion of the transaction, the chief executive officer directly owned 615,898 shares of the company’s stock, valued at $12,059,282.84. The trade was a 7.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 426,127 shares of company stock worth $7,426,087. Insiders own 5.04% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Commodore Capital LP purchased a new position in Relay Therapeutics during the 2nd quarter valued at about $46,191,000. Perceptive Advisors LLC increased its position in shares of Relay Therapeutics by 412.3% during the first quarter. Perceptive Advisors LLC now owns 9,751,141 shares of the company’s stock valued at $97,024,000 after buying an additional 7,847,896 shares during the period. Spruce Street Capital LP purchased a new stake in shares of Relay Therapeutics in the fourth quarter worth about $25,246,000. EcoR1 Capital LLC purchased a new stake in shares of Relay Therapeutics in the first quarter worth about $18,952,000. Finally, TCG Crossover Management LLC bought a new position in shares of Relay Therapeutics in the third quarter valued at approximately $9,450,000. Institutional investors own 96.98% of the company’s stock.

Relay Therapeutics Company Profile

(Get Free Report)

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.